Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Aromatase inhibitors (AIs) are drugs that many people take for several years after initial breast cancer treatment. They are designed to reduce the chance that the breast cancer will come back. However, people who take AIs often develop a type of joint pain known as aromatase inhibitor-associated arthralgia (AIA). Those with AIA often reduce their physical activity and have an increased risk of falling. Some people stop taking their AIs because of this pain.
Researchers in this study are assessing the combination of enfortumab vedotin with pembrolizumab immunotherapy in people with bladder cancer that has spread to nearby lymph nodes and will be surgically removed. Both medications are already used to treat bladder cancer, but their use together before surgery is considered investigational. Both drugs help the immune system attack and kill cancer cells. The study investigators will see if this combination treatment can get rid of cancer in the lymph nodes and shrink patients' tumors before surgery.
The purpose of this study is to assess the safety and effectiveness of treatment with axitinib and nivolumab immunotherapy for people with advanced mucosal melanoma that has not yet been treated. Axitinib blocks the development of blood vessels that cancer cells need to grow and spread ("angiogenesis"). Nivolumab boosts the ability of the immune system to detect and destroy cancer cells.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are comparing AZD0901 with standard treatments in people with advanced gastric cancer. The people in this study have cancer of the stomach or the junction between the esophagus and stomach (gastroesophageal junction). The people in this study have cancers that make a protein called Claudin18.2 (CLDN18.2).
Researchers are comparing IMA203 cellular therapy with standard treatment in people with melanoma of the skin. Their melanoma is inoperable (cannot be surgically removed) or metastatic (has spread) and keeps growing despite treatment.
Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:
In this study, researchers want to learn if tigilanol tiglate is safe and works well against advanced soft tissue sarcoma. When injected into a tumor, tigilanol tiglate stops the blood supply to the cancer, which starves the tumor of nutrients. It may also make the immune system target and kill cancer cells.
Researchers want to find the best dose of xaluritamig to treat prostate cancer. The people in this study have prostate cancer that has not metastasized (spread) but keeps growing after treatment. Their doctors believe their cancers may respond to hormonal therapies that lower cancer-fueling testosterone. This type of cancer is called non-metastatic castration-sensitive prostate cancer.
Researchers want to see if it is practical to give immunotherapy before kidney cancer surgery. The people in this study have no evidence of cancer spread in other parts of their body. Researchers also want to see if this treatment causes any delays in surgery. Immunotherapy is treatment that boosts the body's natural defenses to fight cancer.
